Prosecution Insights
Prosecution Insights
48 pending office actions • 34 clients • 45 examiners • 29 art units • 0 of 48 (0%) have an AI response strategy ready • 74 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 47 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 47 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 23 (48%) |
| §102 only | 3 (6%) |
| §112 only | 5 (10%) |
| No statute on record | 17 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 2 | 81.3% | +12.9% |
| HAVLIN, ROBERT H | 2 | 52.3% | +27.2% |
| JOHNSON, KARA D | 2 | 69.1% | +24.2% |
| KEOGH, MATTHEW R | 1 | 78.6% | +14.0% |
| PIPIC, ALMA | 1 | 54.5% | +55.6% |
| REGA, KYLE THOMAS | 1 | 62.4% | +43.9% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
| HUDSON, AMY ROSE | 1 | 75.1% | +11.4% |
| DUBOIS, PHILIP A | 1 | 25.0% | +25.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.4% | +7.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18543912 | PSGL-1 Antagonists and Uses Thereof | LANDSMAN, ROBERT S | 9d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18450498 | Product for the Storage of Freeze-Dried Lactic Acid Bacteria Mixed with Oral Rehydration Solution | DUBOIS, PHILIP A | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | REGA, KYLE THOMAS | 50d overdue |
| 18450498 | Product for the Storage of Freeze-Dried Lactic Acid Bacteria Mixed with Oral Rehydration Solution | DUBOIS, PHILIP A | 43d overdue |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 18543912 | PSGL-1 Antagonists and Uses Thereof | LANDSMAN, ROBERT S | 9d overdue |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | HUDSON, AMY ROSE | 9d overdue |
| 18070908 | Compositions Derived from Placenta and Methods of Producing the Same | JOHNSON, KARA D | 5d |
| 18274180 | DENATONIUM SALT FOR USE IN PREVENTING, PREVENTING PROGRESSION AND TREATING FATTY LIVER DISEASES | HAVLIN, ROBERT H | 34d |
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | PIPIC, ALMA | 53d |
| Art Unit | Apps |
|---|---|
| 1647 | 5 |
| 1675 | 3 |
| 1626 | 3 |
| 1642 | 3 |
| 1636 | 2 |
| 1623 | 2 |
| 1621 | 2 |
| 1684 | 2 |
| 1627 | 2 |
| 1632 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18844546 | Modulation of Protein Levels | Carlsberg A/S | KEOGH, MATTHEW R | 1663 | §103 | Non-Final OA | 60d | Pending | Sep 06, 2024 |
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | Lapix Therapeutics, Inc. | PIPIC, ALMA | 1617 | §103 | Non-Final OA | 53d | Pending | Jan 17, 2024 |
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 50d overdue | Pending | Jan 17, 2024 |
| 18543912 | PSGL-1 Antagonists and Uses Thereof | Five Prime Therapeutics, Inc. | LANDSMAN, ROBERT S | 1647 | §102 | Non-Final OA | 9d overdue | Pending | Dec 18, 2023 |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | Csl Behring LLC | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 70d | Pending | Nov 20, 2023 |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | Mina Therapeutics Limited | HUDSON, AMY ROSE | 1636 | §102 | Non-Final OA | 9d overdue | Pending | Sep 15, 2023 |
| 18450498 | Product for the Storage of Freeze-Dried Lactic Acid Bacteria Mixed with Oral Rehydration Solution | BIOGAIA AB | DUBOIS, PHILIP A | 1791 | §103 | Non-Final OA | 43d overdue | Pending | Aug 16, 2023 |
| 18276309 | Compounds and Their Use as PDE4 Activators | Mironid Limited | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | 14d | Pending | Aug 08, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | Inhibrx Biosciences, Inc. | CESARE, JOSEPH DAVID | 1675 | Other | Non-Final OA | 5d | Pending | Aug 07, 2023 |
| 18274180 | DENATONIUM SALT FOR USE IN PREVENTING, PREVENTING PROGRESSION AND TREATING FATTY LIVER DISEASES | Aardvark Therapeutics Inc. | HAVLIN, ROBERT H | 1626 | Other | Final Rejection | 34d | Pending | Jul 25, 2023 |
| 18357007 | Antibodies Binding to Human PAD4 and Uses Thereof | Bristol-Myers Squibb Company | GURLEY, JAMI MICHELLE | 1647 | §112 | Non-Final OA | 41d | Pending | Jul 21, 2023 |
| 18223768 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | Celgene Corporation | VALLE, ERNESTO | 1623 | §112 | Non-Final OA | 13d | Pending | Jul 19, 2023 |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | Seagen Inc. | BORGEEST, CHRISTINA M | 1675 | Other | Non-Final OA | 13d | Pending | Jun 14, 2023 |
| 18256516 | Biomarkers for Detecting Cancer | UNIVERSITY OF CAPE TOWN | COOK, LISA V | 1642 | §103 | Non-Final OA | 4d overdue | Pending | Jun 08, 2023 |
| 18323488 | Methods and Treatment for Complex Lymphatic Malformations | Avalo, Inc. | KOSTURKO, GEORGE W | 1621 | §103 | Non-Final OA | 49d overdue | Pending | May 25, 2023 |
| 18035246 | METHOD FOR ENZYMATIC AND/OR MICROBIAL PROCESSING OF WASTE COMPRISING RECIRCULATION OF PROCESS WATER | Renescience A/S | ZINGARELLI, SANDRA | 1653 | §103 | Non-Final OA | 66d overdue | Pending | May 03, 2023 |
| 18251523 | Combination Treatment of Cancer | Glaxosmithkline Intellectual Property (No. 4) Ltd. | XIAO, YAN | 1642 | §103 | Non-Final OA | 8d | Pending | May 02, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | The Scripps Research Institute | FLINDERS, JEREMY C | 1684 | §103 | Non-Final OA | 10d overdue | Pending | Apr 21, 2023 |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | Cancer Research Technology Limited | HSU, GRACE CHING | 1627 | Other | Non-Final OA | 46d overdue | Pending | Apr 18, 2023 |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Woolsey Pharmaceuticals, Inc. | BAUER, NICOLA MARIA | 1621 | §103 | Non-Final OA | 59d overdue | Pending | Apr 14, 2023 |
| 18132278 | Polynucleotides, Compositions, and Methods for Genome Editing | Intellia Therapeutics, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Final Rejection | 147d overdue | Pending | Apr 07, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Sorrento Therapeutics, Inc. | GAMETT, DANIEL C | 1647 | §103 | Non-Final OA | 104d overdue | Pending | Apr 06, 2023 |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | PATTERSON, SARAH COOPER | 1675 | Other | Non-Final OA | 7d | Pending | Dec 20, 2022 |
| 18001514 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT VASCULAR DEMENTIA | Woolsey Pharmaceuticals, Inc. | SONG, JIANFENG | 1613 | Other | Final Rejection | 88d overdue | Pending | Dec 12, 2022 |
| 17928427 | Methods and Treatment Involving Antibodies to IL-18 | Avalo, Inc. | LANDSMAN, ROBERT S | 1647 | — | Final Rejection | 55d | Pending | Nov 29, 2022 |
| 18070908 | Compositions Derived from Placenta and Methods of Producing the Same | StimLabs, LLC | JOHNSON, KARA D | 1632 | Other | Non-Final OA | 5d | Pending | Nov 29, 2022 |
| 17985558 | Monitoring Cancer Stem Cells | Stemline Therapeutics, Inc. | CANELLA, KAREN A | 1643 | Other | Non-Final OA | 78d overdue | Pending | Nov 11, 2022 |
| 18050333 | Methods of in Vitro Cell Delivery | Intellia Therapeutics, Inc. | ZHU, JIANJIAN | 1631 | Other | Non-Final OA | 6d | Pending | Oct 27, 2022 |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | Avm Biotechnology, LLC | HAVLIN, ROBERT H | 1626 | §103 | Non-Final OA | 23d overdue | Pending | Oct 25, 2022 |
| 17911808 | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection | Vitaeris Inc. | BUNNER, BRIDGET E | 1647 | §103 | Non-Final OA | 9d | Pending | Sep 15, 2022 |
| 17801293 | Lymphocyte Population and Methods for Producing Same | Avm Biotechnology, LLC | CHICKS, ASHLI ARIANA | 1626 | §103 | Non-Final OA | 27d | Pending | Aug 22, 2022 |
| 17858146 | Compositions Derived from Placenta and Methods of Producing the Same | StimLabs, LLC | JOHNSON, KARA D | 1632 | §103 | Final Rejection | — | Pending | Jul 06, 2022 |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | Aardvark Therapeutics, Inc. | IVANOVA, SVETLANA M | 1627 | §103 | Non-Final OA | 60d overdue | Pending | Jun 21, 2022 |
| 17836265 | Modified Guide RNAs for Gene Editing | Intellia Therapeutics, Inc. | ARIETI, RUTH SOPHIA | 1635 | Other | Non-Final OA | 30d overdue | Pending | Jun 09, 2022 |
| 17781862 | Medical Composition Comprising Adipose Tissue-Derived Extracellular Matrix And Method For Preparing Same | L&C Bio Co., Ltd. | ALAWADI, SARAH | 1619 | §103 | Final Rejection | 18d overdue | Pending | Jun 02, 2022 |
| 17777402 | Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation Reactions | Kemin Industries, Inc. | CARR, DEBORAH D | 1691 | §103 | Non-Final OA | 72d overdue | Pending | May 17, 2022 |
| 17642800 | Micro-Radiobinding Assays for Ligand Screening | Ac Immune SA | GROSS, CHRISTOPHER M | 1684 | §112 | Non-Final OA | 18d overdue | Pending | Mar 14, 2022 |
| 17639654 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients | Cedars-Sinai Medical Center | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 17d overdue | Pending | Mar 02, 2022 |
| 17637128 | Cardiovascular Risk Event Prediction and Uses Thereof | Somalogic Operating Co., Inc. | GOUGH, TIFFANY MAUREEN | 1651 | §103 | Non-Final OA | 21d | Pending | Feb 22, 2022 |
| 17624043 | Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damage with a CD84 Inhibitor | Julius-Maximilians-Universitaet-Wuerzburg | HOWARD, ZACHARY C | 1674 | §102 | Final Rejection | 99d overdue | Pending | Dec 30, 2021 |
| 17618076 | Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof | Csl Innovation Pty., Ltd. | BELYAVSKYI, MICHAIL A | 1644 | §112 | Final Rejection | 30d | Pending | Dec 10, 2021 |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | Avm Biotechnology, LLC | SANG, HONG | 1646 | Other | Non-Final OA | 14d | Pending | Dec 06, 2021 |
| 17612074 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | King'S College London | DAHLIN, HEATHER RAQUEL | 1629 | Other | Non-Final OA | 12d | Pending | Nov 17, 2021 |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | EDGINGTONGIORDANO, FRANCESCA | 1643 | Other | Final Rejection | 66d overdue | Pending | Jun 25, 2021 |
| 17292025 | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS | Cedars-Sinai Medical Center | SULLIVAN, DENNIS JOHN | 1642 | Other | Final Rejection | 78d overdue | Pending | May 07, 2021 |
| 17111769 | Modified Guide RNAs for Gene Editing | Intellia Therapeutics, Inc. | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | 17d overdue | Pending | Dec 04, 2020 |
| 17028762 | Nucleic Acids for Treatment of Allergies | Immunomic Therapeutics, Inc. | DIBRINO, MARIANNE | 1641 | §103 | Non-Final OA | 156d overdue | Pending | Sep 22, 2020 |
| 16845280 | GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF | Vertex Pharmaceuticals Incorporated | SHIN, DANA H | 1635 | §103 | Final Rejection | 49d overdue | Pending | Apr 10, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial